Share this video  

ESMO Breast 2023 | Detailed safety analysis from the DESTINY-Breast04 trial

Hope Rugo, MD, FASCO, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, reports additional safety data from DESTINY-Breast04 (NCT03734029) which showed that trastuzumab deruxtecan (T-DXd) significantly improved overall and progression-free survival compared to standard-of-care therapy. The median treatment duration for T-DXd was 8.2 months, with lower incidence rates of any-grade treatment-emergent adverse events (TEAEs) compared to TPC. The time to first onset and duration of any-grade interstitial lung disease (ILD) were reported. Some patients with drug-related grade 1 ILD were rechallenged with T-DXd after resolution. T-DXd also had lower incidence of drug-related neutropenia and febrile neutropenia compared to TPC. Nausea/vomiting events were more common with T-DXd, but most resolved with antiemetic prophylaxis. The safety profile of T-DXd supports its use as a new standard of care for HER2-low mBC patients.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.